Investment
Features
FeesSafety
Academy
More
Pluang+

Compare D R Horton Inc (DHI) vs Cassava Sciences Inc (FLNA) Price & Performance

D R Horton IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

D R Horton Inc vs Cassava Sciences Inc — how do they compare? D R Horton Inc trades at $148.96 (market cap $40.79B), while Cassava Sciences Inc trades at $0.95 (market cap $45.09M). The key difference: D R Horton Inc is far larger — about 904.6× Cassava Sciences Inc's market cap, and D R Horton Inc pays a 1.23% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

DHIFLNA
Market Cap
$40.79B$45.09M
Sector
Consumer CyclicalHealth
52-Week High
$184.04$4.64
52-Week Low
$132.53$0.87
Enterprise Value
$45.89B-$37.60M
Dividend Yield
1.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

D R Horton Inc

DHI trades at $146.49, down slightly by 0.12% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $3.20, beating estimates, but revenue guidance for FY2026 was lowered. Valuation ratios appear reasonable with a P/E of 14.37 and P/S of 1.31. Operating cash flow remains strong at $3.42B for 2025, though net cash flow was negative due to significant financing outflows.

The outlook is mixed; disciplined execution supports margins, but weak housing demand and elevated mortgage rates pose headwinds. Analyst consensus is a Buy with a $153 target, offering modest upside. Key risks include persistent affordability pressures and competitive threats from disruptors like Boxabl.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About D R Horton Inc

D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.

Read more on DHI

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA